

101
82. (twice amended) An *in vitro* composition comprising an enriched and expanded population of proliferating dendritic cell precursors.

102
84. (amended) The composition of dendritic cell precursors according to either one of claim 82 or 101 wherein the dendritic cell precursors are human.

103
89. (amended) The composition according to claim 101 wherein the antigen is a microorganism.

104
94. (amended) The composition according to claim 101 wherein the antigen is a mycobacteria tuberculosis bacteria.

105
96. (twice amended) A pharmaceutical composition comprising a therapeutic amount of an enriched and expanded population of human proliferating dendritic cell precursors and a pharmaceutically acceptable carrier.

106
101. (amended) An *in vitro* composition comprising an enriched and expanded population of processed antigen presenting dendritic cell precursors, wherein said dendritic cell precursors present processed antigen derived from said dendritic cell precursors contacted *in vitro*, in the presence of GM-CSF, with antigen for sufficient time for said dendritic cell precursors to process and present said processed antigen.